$GBSN you need to read this
Great Basin Scientific Inc (GBSN) is one of the best performing stocks in the health care sector for companies listed on the New York Stock Exchange or NASDAQ exchange shortly after the opening bell on February 1. Shares of GBSN have climbed 105.56% about 30 minutes into the session to $0.0 after closing the day prior at $0.0. It’s early, but the stock has traded as high as $0.0 and as low as $0.0 so far. Today's quick advance has come with about 56.63 million shares changing hands, compared to an average 30-day volume of 59.39 million for Great Basin Scientific Inc. The price is currently below the 30-day volume weighted average price of $0.0 for GBSN. The share appreciation gives the company a market capitalization of $1,198 based upon 666,013 shares outstanding. It also means that GBSN has a price-to-book ratio of :1 and a price-to-earnings ratio of 0.0:1. In the past 52 weeks, shares of GBSN have traded as low as $0.0016 and as high as $276360.0. Technical traders will take note that at $0.0, shares of GBSN are trading below their 200-day MA at $18850.5 and below their 50-day MA at $2.5. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move through or holding above them is typically regarded as bullish. Who is GBSN? Great Basin Scientific Inc is a molecular diagnostic testing company focused on the development and commercialization of its molecular diagnostic platform for testing for infectious disease, especially hospital-acquired infections. The company’s 134 employees are led by CEO Ryan Ashton from the corporate headquarters at 420 East South Temple. For more information on GBSN and other companies trading on the major exchanges, as well as the over the counter markets, or to be considered for contributing content for our distribution network, visit FinancialPress.com today. All data provided by QuoteMedia, with stock data accurate as of 9:30 AM ET. FinancialPress.com is not responsible for inaccuracies in third-party supplied information. About FinancialPress.com FinancialPress.com is a leading publisher of market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. A complete disclaimer can be viewed here. If you like this article, you can read more at FinancialPress.com
Great Basin Scientific Inc (GBSN) is one of the best performing stocks in the health care sector for companies listed on the New York Stock Exchange or NASDAQ exchange shortly after the opening bell on February 1. Shares of GBSN have climbed 105.56% about 30 minutes into the session to $0.0 after closing the day prior at $0.0. It’s early, but the stock has traded as high as $0.0 and as low as $0.0 so far. Today's quick advance has come with about 56.63 million shares changing hands, compared to an average 30-day volume of 59.39 million for Great Basin Scientific Inc. The price is currently below the 30-day volume weighted average price of $0.0 for GBSN. The share appreciation gives the company a market capitalization of $1,198 based upon 666,013 shares outstanding. It also means that GBSN has a price-to-book ratio of :1 and a price-to-earnings ratio of 0.0:1. In the past 52 weeks, shares of GBSN have traded as low as $0.0016 and as high as $276360.0. Technical traders will take note that at $0.0, shares of GBSN are trading below their 200-day MA at $18850.5 and below their 50-day MA at $2.5. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move through or holding above them is typically regarded as bullish. Who is GBSN? Great Basin Scientific Inc is a molecular diagnostic testing company focused on the development and commercialization of its molecular diagnostic platform for testing for infectious disease, especially hospital-acquired infections. The company’s 134 employees are led by CEO Ryan Ashton from the corporate headquarters at 420 East South Temple. For more information on GBSN and other companies trading on the major exchanges, as well as the over the counter markets, or to be considered for contributing content for our distribution network, visit FinancialPress.com today. All data provided by QuoteMedia, with stock data accurate as of 9:30 AM ET. FinancialPress.com is not responsible for inaccuracies in third-party supplied information. About FinancialPress.com FinancialPress.com is a leading publisher of market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. A complete disclaimer can be viewed here. If you like this article, you can read more at FinancialPress.com
1
@2Eryck
